Salutaris Medical Devices

Answer: Salutaris Medical Devices's phone number is 15*********

Answer: Salutaris Medical Devices's official website is https://salutarismd.com

Answer: Salutaris Medical Devices's revenue is $1 Million to $5 Million

Answer: Salutaris Medical Devices's SIC: 3841

Answer: Salutaris Medical Devices's NAICS: 339112

Answer: Salutaris Medical Devices has 1-10 employees

Answer: Salutaris Medical Devices is in Medical Devices

Answer: Salutaris Medical Devices contact info: Phone number: 15********* Website: https://salutarismd.com

Answer: About Salutaris Medical Devices, Inc (SalutarisMD) SalutarisMD is a pre-revenue medical device company founded to engineer a novel ophthalmic treatment for Wet age-related Macular Degeneration (Wet AMD). We have developed a minimally invasive procedure to provide improved outcomes for the million of patients afflicted with Wet AMD. Our patented and patent pending technology delivers a single-use brachytherapy (radiation) procedure that can be performed in an outpatient setting in approximately 15 minutes. The SalutarisMD device is a practical, clinic-based procedure designed to provide precise lesion-specific targeting. The procedure is performed using a hand-held instrument under the direct care and expertise of the treating retina specialist to deliver localized tissue irradiation, customized for each patient. About Wet Age-related Macular Degeneration Wet Age-related Macular Degeneration is a leading cause of vision loss worldwide. Wet AMD primarily affects the elderly, who represent an increasingly larger proportion of the industrialized worlds population. Annually, <500,000 new cases of Wet AMD are diagnosed in North America and Europe. Ultimately the Asian market will be the largest. According to a study from investigators at Yamagata University Faculty of Medicine, Japan, and others, Among persons aged 40 to 79 years, the age-specific prevalence of late AMD in Asians was comparable with that reported from white populations. Wet AMD is currently a >$8 Billion therapeutic market. The disease is currently treated by chronic, expensive pharmaceuticals (e.g., anti-VEGF drugs Lucentis and Avastin from Genentech/Roche and Eylea from Regeneron/Bayer) that only restore vision in 34%-40% of patients. These available treatment regimens are costly, burdensome and there is a large unmet need for more effective therapies.

Answer:

• LinkedIn